<DOC>
	<DOC>NCT01093911</DOC>
	<brief_summary>To evaluate safety, tolerability, pharmacokinetics and immunogenicity of CDP7657</brief_summary>
	<brief_title>Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Immune System Diseases</mesh_term>
	<mesh_term>Connective Tissue Diseases</mesh_term>
	<criteria>Healthy Volunteers and subjects with SLE Severe neuropsychiatric or severe renal SLE History of chronic, recurrent, or recent severe infection Significant hematologic abnormalities History of cancer, heart failure, renal disease, liver disease or other serious illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Lupus</keyword>
	<keyword>SLE</keyword>
</DOC>